

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Yang Pan  
Application No.: N/A Group No.: N/A  
Filed: Herewith Examiner: N/A  
For: NOVEL MOLECULES OF THE TANGO-93-RELATED PROTEIN FAMILY AND  
USES THEREOF

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or

---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)


37 C.F.R. SECTION 1.10\*

☐ with sufficient postage as first class mail.

☒ as "Express Mail Post Office to Address"  
Mailing Label No. EL961947512US

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Sean Hunziker

(type or print name of person certifying)

Date: December 12, 2003

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MBIO98-048CP2CN1M**

(3) an action that otherwise closes prosecution in the application

whichever occurs first.

[ ] Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

[ ] Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

[ ] No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

**FEE PAYMENT**

[ ] The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

[x] Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

**METHOD OF PAYMENT OF FEE**

[ ] Attached is a check in the amount of \$ \_\_\_\_\_.


[ ] Charge Account No. 501668 in the amount of \$0.00.

[ ] A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

December 12, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By 

Jean M. Silveri  
Attorney for Applicant  
Registration No. 39,030  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-679-7336  
Facsimile - 617 551 8820

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Yang Pan  
Application No.: N/A Group No.: N/A  
Filed: Herewith Examiner: N/A  
For: NOVEL MOLECULES OF THE TANGO-93-RELATED PROTEIN FAMILY AND  
USES THEREOF

**Mail Stop Patent Application**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**INFORMATION DISCLOSURE STATEMENT**

**List of Sections Forming Part of This Information Disclosure Statement**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449)

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Address"  
Mailing Label No. EL961947512US

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Date: December 12, 2003

Signature

  
Sean Hunziker

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Copies of Listed Information Items Accompanying This Statement**

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) were filed with parent application serial number 10/134,410, filed on April 29, 2002.

☒ Exception(s) to above:

Legible copies of References B1-B3 listed in Form PTO/SB/08A (substitute for Form PTO-1449) accompany this information statement.

December 12, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By: 

Jean M. Silveri  
Attorney for Applicant  
Registration No. 39,030  
40 Landsdowne Street  
Cambridge, MA 02139  
Telephone - 617-679-7336  
Facsimile - 617 551 8820

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <h2 style="text-align: center; margin: 10px 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin-top: 10px;"><i>(use as many sheets as necessary)</i></p>				<b>Complete if Known</b>	
		Application Number	N/A		
		Filing Date	Herewith		
		First Named Inventor	Yang Pan		
		Group Art Unit	N/A		
		Examiner Name	N/A		
		Attorney Docket Number	MBIO98-048CP2CN1M		
Sheet	1	of	1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	6,294,655		Ford, et al.	09/25/2001	
	AB	5,455,330		Haskill, et al.	10/03/1995	
	B1	6,337,072		Hyseq, Inc.	01/08/2002	Entire document
	B2	6,426,191		Hyseq, Inc.	7/30/2002	Entire document
	B3	6,541,623		Hyseq, Inc.	04/01/2003	Entire document

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AE	WIPO	99/51744			10/14/1999		
	AF	WIPO	99/35268			07/15/1999		
	AG	WIPO	98/47921			10/29/1998		

Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	N/A
				Filing Date	Herewith
				First Named Inventor	Yang Pan
				Group Art Unit	N/A
				Examiner Name	N/A
Sheet	1	of	1	Attorney Docket Number	MBIO98-048CP2CN1M

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	AJ	Carter, et al., GenPept Accession No. 124312, 15 JUL 1998	
	AK	Carter, et al., "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein", Nature, 334:633-638, 1990	
	AL	Debets, et al., "Two Novel IL-1 Family Members, IL-1δ and UK-1ε, Function as an Antagonist and Agonist of NF-κB Activation Through the Orphan IL-1 Receptor-Related Protein 2", The Journal of Immunology, 167:1440-1446, 2001.	
	AM	Eisenberg, et al., "Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist", Nature, 343:341-346m 1990	
	AN	Marra, et al., Database EST-STS No. W20594, 10 SEP 1996.	
	AO	Marra, et al., Database EST-STS No. W08205, 05 SEP 1996.	
	AP	Matsuchime, et al., "Cloning and Expression of Murine Interleukin-1 Receptor Antagonist in Macrophages Stimulated by Colony-Stimulating Factor 1", Blood, 78(3):616-623, 1991	
	AQ	Zahedi, et al., GenPept Accession No. 124313, 01 NOV 1991.	
	AR	Zahedi, et al., "Mouse IL-1 Receptor Antagonist Protein", The Journal of Immunology, 146:4228-4233, 1991	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.